NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia
· Delayed Price · Currency is AUD
0.105
+0.005 (5.00%)
Mar 10, 2026, 9:59 AM AEST
ASX:NSB Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Net Income | -3.18 | -1.85 | 0.32 | -1.07 | -10.44 | -3.18 | |
| Depreciation & Amortization | 0.67 | 0.09 | 0.09 | 0.06 | 0.06 | 0.06 | |
| Stock-Based Compensation | 0.8 | 0.8 | 0.13 | 0.24 | 1.35 | 0.63 | |
| Other Operating Activities | 0.31 | - | - | - | - | - | |
| Change in Accounts Receivable | -0.04 | -0.04 | -0.01 | 0.08 | -0.07 | -0.03 | |
| Change in Accounts Payable | 0.05 | 0.05 | -0.5 | -1.58 | 1.99 | 0.11 | |
| Change in Other Net Operating Assets | 0 | 0 | 0.01 | -0.03 | 0.16 | -0.19 | |
| Operating Cash Flow | -1.39 | -0.94 | 0.04 | -2.3 | -6.94 | -2.6 | |
| Capital Expenditures | - | - | -0 | - | -0 | -0.03 | |
| Cash Acquisitions | -0.04 | -0.04 | - | - | - | - | |
| Investing Cash Flow | -5.29 | -0.04 | -0 | - | -0 | -0.03 | |
| Issuance of Common Stock | 3.5 | 3.5 | - | - | - | 13.32 | |
| Other Financing Activities | -0.21 | -0.21 | - | - | - | 0.18 | |
| Financing Cash Flow | 3.29 | 3.29 | - | - | - | 13.51 | |
| Net Cash Flow | -3.39 | 2.31 | 0.04 | -2.3 | -6.95 | 10.88 | |
| Free Cash Flow | -1.39 | -0.94 | 0.04 | -2.3 | -6.95 | -2.63 | |
| Free Cash Flow Margin | -436.90% | - | 1.92% | -46.52% | - | -274.46% | |
| Free Cash Flow Per Share | -0.01 | -0.01 | - | -0.02 | -0.05 | -0.02 | |
| Levered Free Cash Flow | -0.31 | -0.34 | -0.19 | -1.97 | -3.08 | -1.49 | |
| Unlevered Free Cash Flow | -0.3 | -0.34 | -0.18 | -1.97 | -3.08 | -1.49 | |
| Change in Working Capital | 0.01 | 0.01 | -0.5 | -1.54 | 2.08 | -0.11 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.